Q2 2026 delivered three simultaneous pivots in longevity and human performance: Lilly's Foundayo became the first oral GLP-1 pill for weight loss (FDA-approved April 1), Isomorphic Labs raised $2.1 billion · the largest private AI drug discovery round in history · and NewLimit secured $435 million from Founders Fund and Lilly Ventures to bring epigenetic reprogramming into human clinical trials. Three separate stories. One direction.